Longboard Pharmaceuticals 2024 Corporate Presentation

Longboard Pharmaceuticals corporate presentation outlining its vision to address devastating neurological conditions through GPCR-focused research. The company highlights its lead candidate bexicaserin (LP352) for drug-resistant epilepsies and LP659 for multiple neurological disorders, supported by 20+ years of research and experienced CNS leadership.